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yses: show that the utility values of all health states are crucial determinants of the 
cost-effectiveness results. CONCLUSIONS: combined therapy resulted in greatest 
health benefits but at the same time it was the most expensive treatment option. 
Behavioral therapy was the least effective and cheapest option.
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OBJECTIVES: The buprenorphine/naloxone (BUP/NAL) combination is used in the 
treatment of prescription opioid drug dependent (OPD) patients. Previous analy-
ses demonstrated that OPD patients receiving treatment vs. no treatment, were 
associated with a reduction in the number of admissions relating to emergency 
care and psychiatric services. The objective of this study was to compare resource 
utilisation and associated healthcare costs between the OPD patients treated with 
buprenorphine/naloxone combination and OPD patients without pharmacologi-
cal treatment from the German healthcare perspective. METHODS: Two patient 
groups were selected: 1) OPD patients treated with buprenorphine/naloxone and 
2) OPD patients with no pharmacological treatment. In the absence of accessible 
large longitudinal administrative claims database in Germany, the resource use 
was estimated based on the Truven Health MarketScan Medicaid (public healthcare 
claims) database from January 01, 2007 to December 31, 2013 as a representation 
of the German population. Resource use included pharmaceutical claims, inpa-
tient care, outpatient care, and urine tests, estimated over twelve months after 
the index date. Drug costs were obtained from the German-specific source (Gelbe 
List PharmIndex) and other unit costs and length of stays using Diagnostic Related 
Group (DRG) and Einheitlicher Bewertungsmasstab (EBM). Sensitivity analyses were 
performed. RESULTS: Costs for OPD patient receiving treatment were lower in all 
categories (inpatient care, outpatient care, and urine tests), except for BUP/NAL cost. 
Total costs over 12 months were 6,033€ and 6,244€ per OPD patient with and with-
out pharmacological treatment, respectively. CONCLUSIONS: Whilst a treatment 
of prescription opioid drug dependent patients with buprenorphine/naloxone is 
associated with a medication acquisition cost, it results in public healthcare savings 
when compared to patients receiving no medication treatment.
PMH36
a Cost effeCtiveness analysis of PHarMaCologiCal and 
PsyCHologiCal interventions in adults witH obsessive CoMPulsive 
disorder
Bryden P.1, Hollingworth W.1, Welton N.J.1, Caldwell D.M.1, Skapinakis P.2
1University of Bristol, BRISTOL, UK, 2University College London, London, UK
OBJECTIVES: Obsessive compulsive disorder (OCD) is the fourth most common mental 
disorder in the UK with a prevalence of 1.5%. UK guidelines recommend either phar-
macological or cognitive behavioural therapy (CBT) for adults with moderate func-
tional impairment. This study estimates the cost effectiveness of pharmacological, 
psychological treatments and combinations of both in the treatment of adults with 
OCD. METHODS: A decision model evaluated the cost effectiveness of selective sero-
tonin re-uptake inhibitors ( SSRIs), venlafaxine (VEN), clomipramine (CLO), behaviour 
therapy (BT), cognitive behavioural therapy (CBT), cognitive therapy (CT), fluvoxam-
ine plus cognitive behavioural therapy (FLV+CBT) and clomipramine plus behaviour 
therapy (CLO + BT). Initial consequences of therapy (0-12 weeks) were modelled using 
a decision tree. Subsequent costs and outcomes were tracked in a Markov model. 
Treatment effects (response based on YBOCS scores) and tolerability (drop outs) were 
obtained from concurrent network meta-analyses. Discounted (3.5%) health service 
costs and benefits (QALYs) over a five year period were estimated, and probabilistic 
sensitivity analyses were conducted to assess robustness of findings. RESULTS: All 
psychological and combined psycho/pharmacotherapy were more costly and had 
better outcomes than pharmacotherapies alone. CT and BT had the highest prob-
abilities (both ≈0.35) of being most cost-effective at UK thresholds. The incremental 
cost per QALY of CBT and FLV+CBT versus SSRIs were £54,280 and £129,318 respec-
tively. CONCLUSIONS: The selection of the most cost-effective therapy for adults with 
OCD is not clear-cut. The high cost-effectiveness of CT and BT is sensitive to exclusion 
of RCTs at high risk of bias. Our results are not inconsistent with UK guidance and sug-
gest that CBT is slightly more efficacious than SSRIs, but is initially more expensive. 
If an SSRI is used, the choice of drug has important economic implications. Tailoring 
the format and intensity of CBT might make it more cost-effective.
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OBJECTIVES: Schizoaffective disorder (SCA) is a complex illness with interplay of 
psychosis and mood symptoms managed with non-optimal pharmacologic regi-
mens that include antipsychotics, mood stabilizers, and antidepressants.1 The 
15-month Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of 
Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective 
Disorder demonstrated the benefit in delayed relapses and reduced risk of relapse 
with paliperidone palmitate once-monthly injectable (PP1M).2 This analysis esti-
mated medical costs differences among patients treated with PP1M monotherapy 
or PP1M adjunctive therapy to antidepressants or mood stabilizers versus pla-
cebo. METHODS: Rates of relapses and serious and non-serious treatment-emer-
gent adverse events (TEAEs) were derived from the trial data. Incremental annual 
medical costs for clinical events from a U.S. payer perspective were obtained from 
literatures and inflation adjusted to 2014 costs. Mean differences in total annual 
medical costs for patients treated with PP1M monotherapy and adjunctive therapy 
versus placebo were then estimated. One-way and Monte Carlo sensitivity analyses 
were additionally carried out. RESULTS: A lower rate of relapses (adjunctive therapy: 
-15.42%; monotherapy: -21.34%) and serious TEAEs (both PP1M cohorts: -3.92%) were 
associated with use of PP1M versus placebo. The average annual medical cost-offset 
per patient was -$8320.92 for monotherapy and -$6030.65 for adjunctive therapy 
driven by reduction in relapse rates and serious TEAEs. One-way sensitivity analysis 
showed that variations in relapse rates had the greatest impact on the estimated 
medical cost difference (monotherapy range: -$11,036.64, -$4,684.93; adjunctive 
therapy range: -$9,650.33, -$1,372.78). CONCLUSIONS: Use of PP1M was associated 
with significantly lower relapse rates and consequently a substantial reduction in 
medical costs. Patients treated with PP1M monotherapy resulted in even a greater 
medical cost saving. Further evaluation to assess the impact of monotherapy option 
in real-world setting is warranted.
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OBJECTIVES: Reductions in prices following the expiry of patents on second-
generation antipsychotics means that they could be made available to patients 
with Schizophrenia in low-income countries. In this study we examine the cost-
effectiveness of of 5 antipsychotics—chlorpromazine, haloperidol, risperidone, 
olanzapine and quetiapine—for the treatment of Schizophrenia in Uganda to 
inform national-level policy and clinical decision making. METHODS: We devel-
oped a decision-analytic 3-state (outpatient, inpatient, and dead) Markov model 
to represent the clinical course of Schizophrenia and the experience of the aver-
age patient with the Uganda healthcare system. The model was run for a base 
population of 18-year-old patients attending Butabika National Referral Mental 
Hospital, in 3-monthly cycles over a lifetime horizon. Parameters were derived 
from a primary chart abstraction study, a local community pharmacy survey, 
published literature and expert opinion where necessary. We computed mean 
DALYs and costs (in $US) for each antipsychotic, incremental cost and DALYs 
averted as well as Incremental Cost Effectiveness Ratios (ICER). RESULTS: In the 
base-case analysis, mean DALYs were highest with chlorpromazine (30.17), fol-
lowed by haloperidol (29.48), while olanzapine (28.90) and risperidone had the 
lowest DALYs (28.99). Expected costs were highest with quetiapine ($6,777), and 
lowest with haloperidol ($6,404). Compared to chlorpromazine, haloperidol was 
a dominant strategy (i.e., it was less costly and more effective). ICERs comparing 
risperidone to haloperidol and olanzapine to risperidone were $372 and $1400 
per DALY averted. CONCLUSIONS: Policy makers and clinicians should consider 
haloperidol as the first line agent for Schizophrenia in Uganda. Further, at com-
monly accepted thresholds (between 1 and 3 times the Gross Domestic Product 
of Uganda), risperidone is highly cost-effective and olanzapine is cost-effective, 
therefore policymakers should consider adding these agents to essential medi-
cines lists for treatment of Schizophrenia.
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OBJECTIVES: The primary objective was to estimate incremental cost-effectiveness 
of vortioxetine, a serotonin modulator and simulator (SMS) versus desvenlafaxine, 
a serotonin-norepinephrine reuptake inhibitor (SNRI), as potential first line medi-
cations for treatment of mild or moderate major depression. The clinical benefit 
of a SMS may be in faster onset and shorter time to remission. Evidence suggests 
vortioxetine causes fewer adverse drug events (ADEs) than desvenlafaxine, which 
has implications for discontinuation of therapy. METHODS: A decision tree was 
constructed to model the cost effectiveness of these two agents from the societal 
perspective. Parameters were obtained from published clinical trial data, a meta-
analysis using indirect treatment comparison, observational studies, preference 
elicitation studies, and cost estimates from Average Wholesale Prices for medica-
tions and claims analyses for cost of medical care. The model assumed that patients 
achieved remission. The time horizon was 48 weeks and included opportunities 
to switch medication therapy at 8 weeks and relapse at 24 weeks. Incremental 
cost-effectiveness ratios (ICERs) were calculated using the number of discontinu-
ations averted, relapses averted, and quality adjusted life years (QALYs) gained as 
outcomes. One-way sensitivity analyses were conducted. RESULTS: The ICER was 
$77,800 per QALY gained, $59,500 per relapse averted, and $58,500 per averted dis-
continuation due to ADEs. The parameter that was least robust was a utility value 
of maintenance therapy for vortioxetine or desvenlafaxine applied to weeks 8-48 
(0.80, range: 0.78-0.82; 0.76, range 0.74-0.78, respectively). Time to remission was 
varied from 6-10 weeks. A shorter time to remission for vortioxetine provided mod-
est improvements in the ICER while a longer time to remission increased cost over 
the point estimate of $77,800 per QALY gained ($69,000-$88,900 per QALY gained, 
respectively). CONCLUSIONS: Model results suggest that there is value in invest-
ing in vortioxetine over desvenlafaxine. A potentially faster time to remission for 
vortioxetine would result in increased value.
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